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Background: Preoperative radiochemotherapy (RCT) is standard in locally advanced rectal cancer (LARC). Initial data
suggest that the tumor’s metabolic response, i.e. reduction of its 18 F-FDG uptake compared with the baseline,
observed after two weeks of RCT, may correlate with histopathological response. This prospective study evaluated
the ability of a very early metabolic response, seen after only one week of RCT, to predict the histopathological
response to treatment.
Methods: Twenty patients with LARC who received standard RCT regimen followed by radical surgery participated
in this study. Maximum standardized uptake value (SUV-MAX), measured by PET-CT imaging at baseline and on day
8 of RCT, and the changes in FDG uptake (ΔSUV-MAX), were compared with the histopathological response at
surgery. Response was classified by tumor regression grade (TRG) and by achievement of pathological complete
response (pCR).
Results: Absolute SUV-MAX values at both time points did not correlate with histopathological response. However,
patients with pCR had a larger drop in SUV-MAX after one week of RCT (median: -35.31% vs −18.42%, p = 0.046). In
contrast, TRG did not correlate with ΔSUV-MAX. The changes in FGD-uptake predicted accurately the achievement
of pCR: only patients with a decrease of more than 32% in SUV-MAX had pCR while none of those whose tumors
did not show any decrease in SUV-MAX had pCR.
Conclusions: A decrease in ΔSUV-MAX after only one week of RCT for LARC may be able to predict the
achievement of pCR in the post-RCT surgical specimen. Validation in a larger independent cohort is planned.
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Preoperative radiochemotherapy (RCT) is standard in lo-
cally advanced rectal cancer (LARC) [1-3]. This treat-
ment is highly effective; tumor down-staging is common
and in 15-30% of patients a pathological complete re-
sponse (pCR) is achieved [4,5]. In light of the correlation* Correspondence: brennerb@clalit.org.i
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reproduction in any medium, provided the orbetween tumor histopathological response and patient
outcome, this response is commonly used as a surrogate
for efficacy [6-8]. However, histopathological response is
known only after surgery, when RCT can no longer be
modified. Therefore, attempts are being made to develop
methods for its early prediction.
One of the leading candidate predictive markers for
histopathological response is 18-fluorodeoxyglucose (FDG)
positron emission tomography (PET)-computerized tom-
ography (CT). Multiple studies reported a correlation
between metabolic response, i.e. the reduction of the
tumor’s FDG uptake following RCT, and histopathologicalral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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uated the metabolic response by comparing the baseline
PET-CT scan, done just before RCT, and a scan done
after its completion [5,9-12]. Yet, such information does
not enable modification or interruption of RCT. Few
studies reported an earlier prediction of histopathological
response in LARC based on PET-CT performed during
RCT [13-19]. Nevertheless, data on prediction of re-
sponse to preoperative therapy for LARC using early
metabolic response as a surrogate are still very limited,
and are almost invariably based on PET-CT done toward
the midst of RCT. The purpose of our study was to pro-
spectively evaluate the ability of a very early metabolic
response, after only one week of RCT, to predict response
to treatment.Methods
Patients
This prospective study included 20 patients who
received preoperative RCT for LARC at the Rabin
Medical Center (RMC), Beilinson Hospital, Israel, be-
tween February 2008 and July 2009. The study was
approved by the institutional ethics committee and
written informed consent was obtained. Eligibility cri-
teria included histologically confirmed primary (non-
recurrent) LARC, defined as uT3-4NxM0 or uTxN+M0
disease according to the American Joint Committee on
Cancer (AJCC) version 7 [20]. Baseline staging work-up
included rigid proctorectoscopy, endoscopic ultrasound
(EUS) and whole body PET-CT. Other inclusion criteria
included FDG-avid tumors, Eastern Cooperative Oncol-
ogy Group (ECOG) performance status <2 and good
organ function. All patients were planned for pre-
operative RCT followed by surgery. The main exclusion
criteria included prior chemotherapy or radiotherapy
for any cause or surgery for rectal cancer and hypersen-
sitivity to 18FDG.Radiochemotherapy
RCT consisted of radiotherapy (RT) with concurrent
fluoropyrimidine-based chemotherapy. The RT protocol
was standard: 45 Gray (Gy) delivered in 1.8 Gy daily
fractions, 5 times per week, and a boost to the tumor of
5.4-9.0 Gy. The dose was prescribed to the isodose
encompassing the primary tumor and the internal iliac
nodes using 6 or 18 MV photons.
Chemotherapy started on the first day of RT and con-
tinued until its completion. It consisted of one of three
regimens: continuous infusion (CI) of 5-fluorouracil
(5FU) 180 mg/m2/d or oral administration of capecita-
bine 825 mg/m2 x 2/d or UFT 300 mg/m2/d, all given
on the days of RT delivery.PET-CT evaluation protocol
Patients performed a baseline PET-CT within two weeks
prior to initiation of RCT. A second scan was done after
one week of treatment, with 24 hour confidence margins
(i.e. scans were done after 6–8 days of RCT).
Surgery
Prior to surgery, patients were restaged with rigid proc-
torectoscopy, abdominal and pelvic CT, EUS and occa-
sionally PET-CT. Radical surgery, including total
mesorectal excision (TME), was scheduled 6–10 weeks
after the completion of RCT. The type of surgery, low
anterior resection (LAR) or abdominoperineal resection
(APR), was at the discretion of the surgeon.
Histopathological tumor response evaluation
Histopathological tumor response was determined by a
single expert pathologist (SM), who was blinded to the
corresponding metabolic response. Response was classi-
fied twice, by achievement of pCR and by tumor regres-
sion grade (TRG). TRG was classified as proposed by
Mandard et al. [21], from complete tumor response
(TRG I) gradually to no regressive changes within the
tumor (TRG V). As data regarding the separation of
responders and non-responders according to the TRG
classification are inconsistent [7,22,23], patients were
compared using individual as well as combined categor-
ies (e.g. I-II vs III-V). While TRG relates only to the pri-
mary tumor, pCR relates to the nodal status too.
Accordingly, pCR was defined as no evidence of residual
tumor, neither in the rectal wall (pT0) nor in the re-
gional lymph nodes (pN0).
PET-CT imaging and processing
Patients fasted for a minimum of 4 hours and blood
sugar level was confirmed to be lower than 200 mg/dl
immediately before the intravenous injection of 370–
666 MBq of FDG. All images were obtained 60 minutes
later by using an integrated eight-sectiony PET-CT scan-
ner (Discovery ST; GE Medical Systems, Milwaukee,
Wis).
Patients drank oral contrast fluid (300 mg Telebrix).
Parameters for limited CT scan of the region of interest
(pelvis) were identical for both studies as follows: helical
CT at 0.8 second/rotation; 100–300 mAs; 120 kVp; sec-
tion thickness, 3.75 mm with 3.75-mm interval. Iodine
contrast medium (Ultravist 300) was administered intra-
venously during CT scan, unless iodine allergy, border-
line renal function or patient refusal. Immediately after
CT, PET was performed. The acquisition time for emis-
sion scans was 3–4 minutes per bed position with a one-
section overlap CT data used for attenuation correction.
Images were reconstructed with a standard iterative
algorithm.
Table 1 Patient and tumor characteristic at presentation
Number %
Age, yrs




Distance from anal verge
< 5 cm 4 20
5-8 cm 11 55








IIA (T3N0) 11 55
IIIB (T3-T4N1) 8 40









Table 2 Treatment details and results
Number %
Radiotherapy dose (Gy)
Median (range) (50.4-54) 51.12




CI 5FU 2 10
Interval between RCT and surgery (weeks)



















Abbreviations: CI 5FU - continuous infusion of 5-fluorouracil.
UFT - tegafur-uracil, RCT – radiochemotherapy.
LAR – Low anterior resection, APR – Abdomino-perineal resection.
1One patient was removed from per – protocol analysis because of delayed
operation.
2Including one patient who had APR and synchronous metastatectomy of liver
metastasis.
Goldberg et al. Radiation Oncology 2012, 7:124 Page 3 of 9
http://www.ro-journal.com/content/7/1/124PET-CT analysis
Visual and semi-quantitative analysis was performed and
the maximum standardized uptake value (SUV-MAX)
calculated in the rectal lesion at baseline and after one
week of RCT. The changes were expressed as the per-
centage of SUV reduction (ΔSUV-MAX). Each PET-CT
reading was done separately by two expert radiologists
(NG, HB), who were blinded to the timing of the study
and to any information on clinical or histological re-
sponse. The final results were averages of the two separ-
ate readings.
Statistical analysis
To evaluate the separation between patients who
achieved pCR and those who did not and between
responders and non-responders per TRG regarding the
change of SUV-MAX values between baseline and day 8
PET-CTs, the Mann–Whitney test was used. As re-
sponse per TRG is still unsettled (see above), the changeof SUV-MAX values were also compared between indi-
vidual TRG categories using the Kruskal-Wallis test. Re-
ceiver operating characteristic (ROC) analysis was used
to find a cutoff for the tests. Analyses were done two-
sided at a 5% significance level.
To define the study’s sample size, we assumed that a
15% decrease in tumor SUV-MAX value will identify
metabolic response, based on the recommendations of
the European Organization for Research and Treatment
of Cancer (EORTC) PET study group [24]. Hence, the
minimal sample size required to achieve a 95% power
level was 16 patients. Our sample size was therefore 20
patients.
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Patients
Twenty patients were included in the study. The patient
and tumor characteristics at presentation are summar-
ized in Table 1. The median age was 65 years, with an
even gender distribution. The majority of tumors (80%)
were located ≥5 cm from the anus. There was a similar
proportion of clinical stage II and III disease. When
these data were available, most tumors were found to be
well to moderately differentiated.
Treatment
Treatment details and results are depicted in Table 2.
All patients received standard RCT, consisting of an RT
dose of 50.4-54.0 Gy and concurrent chemotherapy,
most commonly capecitabine. All but one underwent
surgery within 6–10 weeks (median: 8.7 weeks) after
RCT completion, as per protocol. One patient was oper-
ated 21 weeks after RCT due to a femoral fracture and
was excluded from the analysis. Ninety-five percent
underwent curative (R0) resection and 80% had LAR.
Following surgery, 4 patients (20%) had complete dis-
appearance of their primary tumor (pT0) and 14 (70%)
had no lymph node involvement (pN0). One patient had
a single distant metastasis in the liver (pM1), which was
found at surgery and was resected. Four patients (20%)
achieved pCR and 6 (30%) had tumors with TRG I-II,
grades that are considered as representing histopatho-
logical response. None had TRG V, i.e. all tumors had
some response. The histopathological appearance of rep-
resentative cases of a complete responder and a non-
responder is presented in Figure 1.
PET-CT evaluation
Data on individual patients’ metabolic and histopatho-
logical responses are shown in Table 3. The median
SUV-MAX values at baseline and at the second scan
were 20 (range, 7.5-56) and 17 (range, 5.8-37.9), respect-
ively. Reduction of FDG uptake was observed in 14Figure 1 The histopathological appearance of representative cases of a
In the case of a complete responder (Figure 1A), the mucosa was eroded a
microcalcifications. No residual tumor was found. In the case of a non-resp
regression grade [TRG] IV). Abundant tumor was found, with minimal fibrospatients (70%), with a maximum decrease of 45.2%
(range: 15.3%-45.2%). In 5 patients (25%) SUV-MAX
values increased, with a maximum increase of 85%
(range: 1.6%-85.3%), and in one patient (5%) it remained
unchanged. As mentioned, one patient was excluded
from further analysis for delayed surgery.
Correlation between metabolic and histopathological
response
The distribution of SUV-max values at baseline and after
one week of RCT according to histopathological re-
sponse is illustrated in Figure 2. There was no significant
difference in SUV-MAX values at baseline or at day 8
(p = 0.617 and p = 0.841, respectively) between patients
who did (n = 4) and those who did not achieve pCR
(n = 15) (Figure 2A). Similarly, no correlation was found
between SUV-MAX values at these time points and re-
sponse per TRG. For example, patients with TRG I-II
and those with TRG III-IV had almost identical values at
both tests (p = 0.759 and p = 0.726, respectively)
(Figure 2B).
We then evaluated the correlation between the extent
of metabolic response after one week of RCT, i.e.
ΔSUV-MAX values, and the histopathological response
(Figure 3). We found a significant difference between
patients who obtained pCR and those who did not:
patients with pCR had a median ΔSUV-MAX of
−35.3% (range: [−8.9%]–[−43.1%]) while patients with-
out pCR had a median ΔSUV-MAX of −18.4% (range:
[85.3%]–[−33%]) (p = 0.046) (Figure 3A). When compar-
ing patients according to TRG, we noted a large vari-
ation between the different TRG categories (Figure 3B)
and a similar decrease in SUV-MAX when comparing
TRG I-II vs TRG III-IV or TRG I-III vs TRG IV
(p = 0.483 and p = 0.841, respectively).
Prediction of histological response
To find a cutoff value of ΔSUV-MAX that will predict
pCR, ROC analysis was done. According to this analysis,complete responder and a non-responder (H&E, magnification X4).
t the tumor site and there was marked fibrosis with focal
onder (Figure 1B), nearly no signs of response were noted (tumor
is and regressive changes between the invasive tumor.













TRG Presence of pCR
1 17.6 12 −5.6 −31.82 III no
2 * 42 23 −19 −45.24 IV no
3 21.3 19.4 −1.9 −8.92 I yes
4 17 13 −4 −23.53 III no
5 16.7 9.5 −7.2 −43.11 I yes
6 17.8 13.5 −4.3 −24.16 III no
7 13 18.5 5.5 42.31 II no
8 15.2 15.2 0 0.00 II no
9 20 13.4 −6.6 −33.00 IV no
10 56 37.9 −18.1 −32.32 I yes
11 23 26 3 13.04 III no
12 28 36 8 28.57 III no
13 18.2 15.4 −2.8 −15.38 III no
14 16.9 13.7 −3.2 −18.93 III no
15 11.9 9.7 −2.2 −18.49 IV no
16 8.9 6.2 −2.7 −30.34 IV no
17 7.5 13.9 6.4 85.33 IV no
18 15.2 12.4 −2.8 −18.42 III no
19 24.6 25 0.4 1.63 III no
20 9.4 5.8 −3.6 −38.30 I yes
Abbreviations: SUV-MAX - maximum standardized uptake value, pCR – pathological complete response.
*Patient was removed from per – protocol analysis because of delayed operation.
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PET-CT scans will predict all patients with pCR. Con-
versely, ΔSUV-MAX ≥0% will accurately predict failure
to achieve pCR. The 0% cutoff provides a sensitivity of
100% and a specificity of 40% for not obtaining pCR,
with a positive predictive value (PPV) of 31% and a
negative predictive value (NPV) of 100%.
On the other hand, a decrease of more than 32% will
predict only patients with pCR. This cutoff gives a sensi-
tivity of 75% and a specificity of 100% for achievingFigure 2 Distribution of SUV-max values at baseline and after one we
Histopathological response was evaluated by the presence or absence of p
are represented by red circles.pCR, with PPV of 100% and NPV of 93%. The predictive
value of metabolic response on pCR, using the two cut-
offs, is summarized in Figure 4. A similar analysis was
not done for TRG as no significant correlation was
found between the SUV-MAX changes and that
outcome.
Discussion
Our results suggest that very early metabolic response,
after one week of preoperative RCT for LARC, canek of RCT according to histopathological response.
CR (Figure 2A) or tumor regression grade (Figure 2B). Extreme values
Figure 3 Distribution of ΔSUV-MAX between baseline and after one week of RCT according to histopathological response.
Histopathological response was evaluated by the presence or absence of pCR (Figure 3A) or tumor regression grade (Figure 3B). Extreme values
are represented by red circles.
Figure 4 Prediction of histological response using early metabolic response.
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score. Furthermore, our findings are consistent with the
accumulating evidence on the predictive role of repeat-
ing FDG-PET-CT during preoperative RCT for LARC.
Seven other studies on this topic, providing data on 221
patients, were reported (Table 4). Five studies suggested
a correlation between early metabolic response and
histopathology at surgery and two were negative. The
main differences between the studies were the timing of
the second PET-CT, the definition of histopathological
response and the cutoffs chosen. In most studies the
subsequent PET-CT was done during or after the second
week of RCT and in one study, by Janssen et al. [14],
patients underwent two scans during RCT, after one and
two weeks. There is no clear correlation between the
results of the studies and the timing of the second PET-
CT; yet, the only study in which PET-CT was repeated
after three weeks was negative [16]. Data on a second
PET-CT after one week of RCT are limited to two stud-
ies. Janssen et al. [14] reported some predictive impact
of metabolic response after one week of RCT but due to
overlap of ΔSUV-MAX values, no cutoff between
responders and non-responders was identified. In our
study, the differences in ΔSUV-MAX after one week of
RCT showed good prediction of histopathological re-
sponse. As the main benefit from early prediction of re-
sponse is the ability to modify the treatment, one should
attempt to predict this response as early as possible,
even after one week. Our results, while still invalidated,
support this approach.
Another important dissimilarity among studies was
the definition of histopathological response. Even theTable 4 Correlation between metabolic and histopathologica
Author (country) Year N 2nd PET
(weeks)
End-point
Cascini13 (Italy) 2006 331 2 TRG
Janssen14 (Netherlands) 2009 30 1 TRG2
2 TRG
Rosenberg15 (Germany) 2009 30 2 TRG
Guerra16 (Italy) 2009 28 3 TRG
Lambrecht17 (Belgium) 2010 223 2 pCR
Janssen19 (Netherlands) 2011 30 2 TRG
214 2 TRG
Leibold1 (USA) 2011 275 1.5 pCR
Current (Israel) 2011 206 1 pCR
TRG
Abbreviations: NR – not relevant, NA – not available.
1Patients received non-standard RCT, including also oxaliplatin and raltitrexed.
2A second end-point was prediction of ypT0-2 vs ypT3-4 by metabolic response.
3Two patients received non-standard RCT, including also oxaliplatin.
4The study included a validation cohort (n = 21); 5 patients were excluded from the
5The study included 4 patients with metastatic disease; responders included compl
6One patient was removed from per – protocol analysis because of delayed operatiTRG classification varied: while four studies used the
classical Mandard’s definition [21], one used the Becker’s
definition [25]. Similarly, the three studies using pCR as
endpoint were inconsistent: while we and Lambrecht
et al. [17] defined response only as pCR, Leibold et al.
[18] included also near pCR, i.e. extensive yet incom-
plete tumor destruction. It is unclear if the inclusion of
tumors with less extensive and maybe slower response
as “responding tumors” lead to the negative results of
the latter trial. Obviously, each definition of histological
response has advantages and disadvantages. For ex-
ample, while predicting pCR may be more useful when
one considers avoiding or minimizing surgery, it neglects
patients with less extensive response who may still bene-
fit from RCT. We believe that pCR is currently the ad-
equate endpoint for future studies, as its prognostic
impact is well established and its practical implications
are clear [7,8,22,26,27].
The reported different cutoffs of 30-50% drop of SUV-
MAX in the second PET-CT reflect multiple methodo-
logical variations between studies, including the PET-CT
protocol and timing and the definition of histopatho-
logical response, as well as some intrinsic variability of
the test. Most importantly, cutoffs were chosen from
ROC curves, reflecting the investigator’s preference of
the balance between the sensitivity and specificity of the
test. Hence, the utility of two different cutoffs might be
helpful. For example, if one is mostly concerned about
false positive pCR, he may use a cutoff with maximal
PPV (32% cutoff in our study); yet if false negative pCR
is more critical, a cutoff providing maximal NPV (0%










62 vs 28 52 100 87 <0.0001
29 vs 9 NA NA NA 0.013
47 vs 18 43 91 82 0.001
44 vs 30 35 82 58 0.085
51 vs 43 49 75 42 NS
59 vs 25 40 60 100 0.0036
NR 48 100 79 <0.001
NR 48 83 93 0.001
27 vs 23 NR NR NR 0.68
35 vs 32 100 94 0.046
1832 vs 17 NR NR NR 0.064
analysis due to peritumoral inflammation.
ete and near complete pathological response (≥95% response).
on.
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and their cutoffs can be further optimized, considering
the clinical needs, toward their validation.
Aside from their size, the most obvious limitation of
the different studies, including ours, is the lack of valid-
ation. The first attempt to validate earlier results of the
same group was reported recently [19]. In the first part
of that study, enrolling 30 patients, the investigators
determined the cutoff of ΔSUV-MAX after two weeks of
RCT to be validated. The cutoff (48%) was indeed vali-
dated in an independent cohort of 21 patients, with high
PPV (83%) and NPV (93%) (p = 0.001). Of note, 10% of
the patients did not enter the analysis due to peritu-
moral inflammatory response [19]. Clearly, this study is
a step in the right direction but more validation studies,
on larger cohorts, are needed.
Conclusions
In summary, this study shows the ability of a very early
metabolic response, after only one week of preoperative
RCT for LARC, to predict the achievement of pCR, but
not TRG. If validated, it may enable practical modifica-
tions of the multi-modality treatment of LARC, such as
referral of non-responders to undelayed surgery or
avoidance of radical surgery in complete responders. A
validation study is planned.
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